Treatment of Tuberculous Lymphadenitis

First-Line Treatment Regimen

The American College of Physicians recommends a 6-month regimen consisting of isoniazid, rifampin, pyrazinamide, and ethambutol for the initial 2 months, followed by isoniazid and rifampin for an additional 4 months (2HRZE/4HR) for the treatment of tuberculous lymphadenitis in adults 1
The standard treatment for tuberculous lymphadenitis follows the same principles as pulmonary tuberculosis, with a 6-month regimen consisting of four drugs initially, followed by two drugs for the continuation phase 1
Standard adult dosing includes isoniazid at 5 mg/kg (up to 300 mg) daily, rifampin at 10 mg/kg (450 mg if <50 kg, 600 mg if >50 kg) daily, pyrazinamide at 35 mg/kg (1.5 g if <50 kg, 2.0 g if >50 kg) daily, and ethambutol at 15 mg/kg daily 1
Rifampin dosing is also supported by 2

Ethambutol may be omitted in patients with a low risk of isoniazid resistance (isoniazid resistance rate <4%) and in previously untreated patients who are HIV-negative 1 2
If pyrazinamide cannot be included in the initial regimen, treatment duration should be extended to 9 months total 2
Directly observed therapy (DOT) is recommended to ensure treatment adherence, particularly for intermittent regimens 1

For HIV-infected patients with tuberculous lymphadenitis, the same 6-month regimen is recommended, but clinical and bacteriologic response must be carefully assessed 1
Pyridoxine (vitamin B6, 25-50 mg daily) should be administered to all HIV-infected patients receiving isoniazid to prevent neurological side effects 2

For children, dosing should be weight-based, with isoniazid at 10-15 mg/kg (up to 300 mg) daily 1
The same 6-month regimen is recommended for children with tuberculous lymphadenitis 1

For isoniazid-resistant tuberculous lymphadenitis, the American Thoracic Society recommends adding a later-generation fluoroquinolone to a 6-month regimen of daily rifampin, ethambutol, and pyrazinamide 1
For multidrug-resistant TB (MDR-TB), which includes resistance to at least isoniazid and rifampin, treatment must be individualized based on susceptibility studies 3
The American Thoracic Society recommends at least five drugs in the intensive phase and four drugs in the continuation phase for MDR-TB treatment 3

Patients should be monitored monthly for treatment response and adverse effects 1

Shorter rifamycin-based regimens (3-4 months) that are now preferred for latent TB infection should not be confused with the 6-month regimen required for active tuberculous lymphadenitis 1
Rifampin interacts with many medications, including oral contraceptives, anticoagulants, and antiretroviral drugs, requiring careful medication review and potential dose adjustments 2